SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today announced that Sharon E. Tetlow has joined
the company as senior vice president and chief financial officer. Ms. Tetlow,
who was most recently a venture partner at Apax Partners, a private equity
firm, brings over 18 years of financial management experience in the life
science industry, including the last five years as chief financial officer for
diaDexus, a pharmacogenomics company. Ms. Tetlow replaces Matthew J. Pfeffer
who is resigning to spend more time with his family.
"We are very pleased to have Sharon join the Cell Genesys management team,
given her proven track record of strategic and financial leadership in the
biotechnology industry," stated Stephen A. Sherwin, M.D., chairman and chief
executive officer. "She will be a real asset to our company as we continue to
advance our clinical pipeline and build value for our shareholders."
Ms. Tetlow, 45, who joins Cell Genesys from Apax Partners, was previously
chief financial officer of diaDexus, where she was successful in raising over
$100 million in equity financing and closing the company's largest financial
alliance with an international diagnostics company. Prior to diaDexus, she
held senior management positions in other biotechnology companies including
chief financial officer at Reprogen and Terrapin Technologies (now Telik), as
well as senior finance positions at Synergen (now part of Amgen) and
Genentech. Earlier in her career, Ms. Tetlow was an associate at the
Brookings Institution in Washington, D.C. Ms. Tetlow holds a Master of
Business Administration from the Graduate School of Business, Stanford
University and a Bachelor of Arts and Science degree magna cum laude, from the
University of Delaware.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and
oncolytic virus therapies. Clinical trials of GVAX(R) cancer vaccines include
an ongoing Phase 3 trial of GVAX(R) vaccine for prostate cancer as well as
trials of GVAX(R) vaccines for leukemia, pancreatic cancer, lung cancer and
myeloma. Clinical programs of oncolytic virus therapies currently include
CG7870 for prostate cancer and CG0070 for bladder cancer. Cell Genesys
continues to hold equity interests in its two former subsidiaries -- Abgenix,
Inc., an antibody products company and Ceregene, Inc., which is developing
gene therapies for neurodegenerative disorders. Cell Genesys is headquartered
in South San Francisco, CA and has manufacturing operations in San Diego, CA,
Hayward, CA and Memphis, TN. For additional information, please visit the
company's website at http://www.cellgenesys.com.
Statements made herein about the company and its subsidiaries, other than
statements of historical fact, including statements about the company's
progress, results and timing of clinical trials and preclinical programs,
agreements with the FDA and the nature of product pipelines are
forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the statements made,
including risks associated with the success of clinical trials and research
and development programs, the regulatory approval process for clinical trials,
potential changes in study protocols, new concerns of safety not previously
known, regulatory agreements for manufacturing controls and product testing
requirements, competitive technologies and products, patents, continuation of
corporate partnerships and the need for additional financings. For information
about these and other risks which may affect Cell Genesys, please see the
company's Annual Report on Form 10-K for the year ended December 31, 2004
dated March 14, 2005, as well as Cell Genesys' reports on Form 10-Q and 8-K
and other reports filed from time to time with the Securities and Exchange
Commission. The company assumes no obligation to update the forward-looking
information in this press release.
Contact: Ina Cu
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations of Cell Genesys,
Inc., +1-650-266-3200
|
